Anti-Microbial Resistance

Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, or parasites no longer respond effectively to medicines. It complicates treatment, increases the risk of severe disease, and can undermine routine healthcare, surgery, cancer care, transplantation, and animal health. The World Health Organization identifies AMR as one of the major global public-health threats, while the 2019 Global Research on Antimicrobial Resistance analysis estimated that bacterial AMR was directly responsible for 1.27 million deaths in 2019 and associated with 4.95 million deaths. Effective responses require coordinated action across human health, veterinary medicine, food production, environmental management, research, and public policy.

The AMR landscape is shifting from reliance on new medicines alone toward a broader prevention and stewardship model. Hospitals and health systems are strengthening infection prevention, diagnostic testing, antimicrobial stewardship, vaccination, and surveillance. Agriculture is facing greater scrutiny over medically important antimicrobial use, with international guidance emphasizing disease prevention, improved husbandry, vaccination, and restricted use for growth promotion. Environmental pathways-including pharmaceutical manufacturing discharges, wastewater, healthcare waste, and agricultural runoff-are receiving increased attention. Progress remains uneven because access to quality-assured diagnostics and effective treatment coexists with inappropriate use, counterfeit or substandard products, weak laboratory capacity, and gaps in surveillance.

Artificial intelligence can support AMR control by helping laboratories interpret genomic and phenotypic data, identify resistance patterns, optimize diagnostic workflows, and support clinical decision-making. Machine-learning tools may also assist outbreak detection, antimicrobial utilization review, drug discovery, and analysis of environmental or animal-health data. Their value depends on representative datasets, transparent validation, interoperability, cybersecurity, and clinical oversight. Bias in training data, limited explainability, privacy risks, and weak performance across low-resource settings can reduce reliability. AI should therefore complement-not replace-microbiologists, infectious-disease specialists, pharmacists, public-health authorities, and veterinarians.

North America generally has extensive surveillance and stewardship infrastructure, but healthcare-associated resistance, outpatient prescribing, and resistant Gram-negative infections remain important priorities. Latin America continues to require stronger laboratory networks, reliable access to diagnostics and quality-assured medicines, and coordinated action across fragmented health systems. Europe benefits from established surveillance and policy coordination, while resistant hospital pathogens, cross-border transmission, and antimicrobial use in community and animal settings remain concerns. The Middle East faces priorities linked to healthcare-associated infections, mobility, conflict-affected systems, and uneven laboratory capacity. Africa carries a substantial burden shaped by limited diagnostics, constrained access to effective treatment, and under-resourced surveillance. Asia-Pacific is highly diverse, combining advanced national programs with major needs in rural access, prescribing oversight, infection prevention, and agricultural and environmental monitoring.

ASEAN members can benefit from interoperable surveillance, regional laboratory collaboration, and coordinated responses to cross-border health threats. BRICS cooperation can support research partnerships, manufacturing resilience, laboratory strengthening, and equitable access while recognizing differences in national systems. The European Union has mechanisms for surveillance, stewardship, preparedness, and coordinated policy, but implementation remains important across member states. G7 collaboration can advance financing, innovation, supply-chain resilience, and global standards. GCC countries can strengthen regional infection-control networks, hospital stewardship, and preparedness for high patient mobility. NATO’s health-security role makes resilient medical supply chains, biosurveillance, and interoperable civil-military preparedness relevant, while AMR action should remain grounded in public-health and One Health principles.

Australia continues to emphasize national surveillance, antimicrobial stewardship, and coordinated One Health planning. Brazil faces the need to expand diagnostics, surveillance, and stewardship across a large and diverse health system. Canada combines established public-health capacity with priorities in community prescribing, agriculture, and resistant infections. China is strengthening stewardship, surveillance, laboratory capability, and research while addressing scale and regional variation. France, Germany, Italy, Spain, and the United Kingdom continue to focus on hospital and community stewardship, infection prevention, surveillance, and prudent veterinary use. India’s priorities include affordable diagnostics, quality-assured treatment, sanitation, and stronger regulation and surveillance. Japan and South Korea emphasize aging-population needs, healthcare-associated infections, and advanced surveillance. Mexico must continue improving laboratory networks, prescribing oversight, and access across regions. Russia’s priorities include surveillance, infection prevention, and reliable access to effective medicines amid system and supply-chain constraints. The United States continues to address resistant pathogens through stewardship, surveillance, diagnostics, prevention, and development incentives.

Leaders should set measurable antimicrobial-use and resistance objectives across human, animal, and environmental operations; strengthen infection prevention and diagnostic stewardship; and ensure treatment decisions are guided by reliable, timely laboratory results. Organizations should invest in interoperable surveillance that combines clinical, laboratory, pharmacy, genomic, veterinary, and wastewater information while protecting privacy and validating analytical tools. Supply-chain strategies should prioritize quality assurance, continuity of essential medicines, and responsible manufacturing. Partnerships with public authorities, hospitals, laboratories, farmers, and communities can improve uptake and local relevance. AI investments should include bias testing, human review, cybersecurity, transparent performance monitoring, and explicit accountability for clinical or operational decisions.

This executive summary is based on a structured review of authoritative public-health and scientific evidence, including global AMR burden research, World Health Organization guidance, national and regional surveillance resources, antimicrobial stewardship frameworks, peer-reviewed literature, and One Health policy documents. Findings were synthesized by comparing evidence across human health, animal health, food systems, and environmental pathways, then organizing implications by region, country, and multilateral group. The analysis prioritizes documented disease burden, established policy directions, surveillance findings, and validated operational challenges. It excludes market estimates, market shares, forecasts, and unsupported claims, and recognizes that surveillance coverage and data quality vary substantially between jurisdictions.

AMR is sustained by interconnected drivers: transmission, inappropriate or unnecessary antimicrobial exposure, inadequate infection prevention, limited diagnostic access, environmental contamination, and uneven availability of effective treatment. No single sector or geography can resolve the problem independently. The most durable response combines prevention, vaccination, diagnostics, stewardship, surveillance, responsible production, research, and equitable access, supported by accountable governance. Regional and country-specific implementation should reflect local evidence and capacity, while international groups can improve interoperability, financing, supply resilience, and preparedness. Leaders that connect operational action with high-quality data and measurable accountability will be better positioned to reduce avoidable infections and preserve antimicrobial effectiveness.